Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer
Crossref DOI link: https://doi.org/10.1007/s11096-023-01580-2
Published Online: 2023-04-20
Published Print: 2023-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kashiwa, Munenobu http://orcid.org/0000-0001-5178-611X
Matsushita, Ryo
Text and Data Mining valid from 2023-04-20
Version of Record valid from 2023-04-20
Article History
Received: 27 October 2022
Accepted: 21 March 2023
First Online: 20 April 2023
Conflicts of interest
: The authors have no conflicts of interest to declare.